Director, Disease Strategy Oncology - Zug, Schweiz - GSK

GSK

Geprüftes Unternehmen

Zug, Schweiz

vor 1 Woche

Geschrieben von:

Lena Schneider

beBee Recruiter

Beschreibung

Site Name:
USA - Pennsylvania - Upper Providence, Switzerland - Zug, UK - Hertfordshire - Stevenage, USA - Massachusetts - Waltham

Posted Date:
Feb

Do you want to be part of a highly regarded and rapidly growing Oncology R&D team focused on improving the lives of cancer patients? If so, the Director - Oncology DATs is an excellent opportunity to explore.

GSK is expanding the Oncology Clinical Development organization and we are seeking experienced professionals to join our exciting journey.

We develop potentially life-changing oncology therapies with a focus in three areas of cancer research: Immuno-Oncology, Tumor Cell Targeting and Synthetic Lethality.

_ This is a hybrid role and can be based at our Upper __Providence, PA, Waltham, MA, Stevenage, UK or Zug, Switzerland_
_ sites._

The Director will be closely working with the cross functional Disease Area Team (DAT) leader and core members of DATs to ensure timely and coordinated development (or updates) of respective GSK Oncology initiatives, including Tumor maps, Efficacy/Safety benchmarking data, aligning on current and future standard of care as well as areas of unmet needs.

As member of cross functional disease or project teams, the Director DAT will also support research, medical affairs and business development projects from the disease are perspective.

This work will include tracking of proper execution of all key elements and action items identified within the individual Disease projects/ initiatives together with respective internal communication and know-ledge sharing plans across R&D and Commercial Functions.

In this capacity, the Director will be a core member of the individual Disease Area Teams, with shared responsibility (together with the DAT Lead) for the proper planning, conduct, follow up and communication of DAT meetings.

The Director will be also responsible for the documentation, storage and system build up to allow all relevant GSK stakeholders and functions to access Disease Area information as needed and in line with GSK policies.

The Director will furthermore closely work with the GSK Research Teams, relevant Medicines Development Teams (MDTs), Early Development Teams (EDTs) and as needed with Commercial Functions to ensure strong communication with asset teams, coordinated, aligned and efficient joint project work.

This work includes at least annual updates of DA information, coordination of governance presentations of MDTs, EDTs and MCTs where DAT input is needed (jointly with respective PMs) and preparation, conduct and follow up of other management meetings.

Additionally, the Director will monitor and control the execution of the plans through their lifecycle while identifying and communicating issues and risks and developing mitigation plans.

This position has the potential to supervise Disease Area Managers (as applicable).

Responsibilities:

Disease Area Information:
Plan, Preparation, Management, Maintenance, Monitoring, and Alignment and Communication

Partner with team member in Clinical Development, MDTs, EDTs, Research Units, the Experimental Medicine Unit, Commercial functions, Business Development and other stakeholder to crosslink different asset or program driven (R & D or Commercial) teams to: support alignment on key assumptions about the current standard of care, efficacy/safety benchmarks per tumor type, molecular pathway maps by tumor, changing treatment algorithm and unmet medical needs in oncology indications.
Track execution of the DA projects against DA objectives and key deliverables. Together with the DAT Leader, translate DA insights and scientific information into a robust, strategic plan of key crossfunctional activities and milestones.
Support external vendor selection process (for strategic topics, workshops etc) as needed and work closely with potential vendor(s) on project work to support timely delivery of (vendor) tasks/action items, including budget planning, allocation, and close monitoring of resource allocations (budget tracking).
Proactively identifies and escalates business issues and considers options to manage implications and risks on project timelines, budgets, and goals.
Monitors progress against approved DA plans, supportive scientific/clinical data and information, noting deviations and suggesting corrective actions.
Integrates activities with all functional lines and with EDTs and MDTs, to create alignment of program development plans functional area plans and Asset plans (i.e., established by MDTs or EDTs)
Building up of source systems and systems that allow DAT stakeholder and relevant GSK functions to access DA Team information as needed and in line with GSK policies.
Ensures source systems reflect the current DA plan assumptions to enable integrated planning across the organization and tracks performance against baseline and current plan.

**Governance and Decision